My Hidden Page...
16 Ideas, 6 Past +75%, 47% Average Peak - And the Page Doing It Has Only 3,000 Subscribers...
To read our full disclaimer, click here:
Before I tell you what page this is, look at the numbers.
16 ideas published.
47% average peak return since publication. Not the best one. The average.
6 of the 16 - 38% - up 75% or more at some point.
Average idea is 155 days old. Five months. The newest is 26.
So here’s my question: what corner of the market do you think produces a hit rate like that, in under six months?
Most people guess wrong. They picture hype - AI, crypto, momentum names.
It’s micro-cap healthcare.
And the page doing it is mine and one most of you may have never heard of…
Read to the end - I’m giving away free subscriptions, plus 25% off for the first five who claim it.
The Page
It’s called The Clinical Edge - the second newsletter I run, pointed entirely at small healthcare companies.
It has about 3,000 subscribers. Multibagger Ideas has roughly 35,000.
The gap doesn’t match the results, so I’m fixing it.
Why Peak Return Is the Number
The Clinical Edge isn’t a hold-for-a-decade page like Multibagger Ideas.
Neither is Real Economy Ideas, the other one I run.
The main newsletter finds a great business and holds it through the messy middle while it compounds for years.
These pages are built for something different: asymmetric upside, where the payoff is often binary and the mispricing sits in the optionality.
A lot of what I cover lives or dies on an event - an FDA decision, a reimbursement ruling, a clinical readout, a contract award.
When the market underprices one of those, the asymmetry can be enormous: capped downside, multiple-bag upside if it breaks right.
That asymmetry is biggest at the start of the trade, before the crowd catches on. Once the catalyst hits and the gap closes, the easy money is made - so the discipline leans toward taking the winner, not holding forever and hoping.
That’s my strategy and why, for me, peak return is the honest headline.
It captures exactly what this approach is designed to produce: the move from underappreciated to repriced.
I’m Upgrading the Page
The track record convinced me this page deserves a lot more than I’ve been giving it. So:
A real posting schedule. Consistent new ideas, consistent updates. No more sporadic drops.
A dedicated research portal. The same one Multibagger Ideas subscribers love - every thesis, update, and position in one searchable place. Included in the price.
More hands on deck. A couple of colleagues joining me to ramp coverage - more ideas surfaced, more catalysts caught in real time.
Same quality bar. Every name still has to clear it: real competitive advantages, management with skin in the game, runway to the next catalyst, multiple ways to win, a market mispricing the optionality.
The Giveaway
Two ways to get in cheaper - or free.
1. Win a free month.
Like and restack this post, and I’ll draw a few winners and hand each a free monthly subscription to The Clinical Edge, on me. The restacks are how a 3,000-subscriber page reaches the audience this track record deserves, so thank you for sharing it.
2. 25% off - first five only.
The button below takes 25% off automatically - no code to enter. It’s capped at five redemptions, so it’s first come, first served. And because annual already runs about a third cheaper than monthly, claiming it on an annual plan stacks two discounts at once and locks in the rate for as long as you stay subscribed, even when prices rise later this year as the portal lands.
16 ideas. 47% average peak. Six past +75% in under six months. One framework, pointed at the most asymmetric corner of the market I know.
I’ve been running this page quietly.
I’m done doing that.
Thanks for reading,
Nico
Disclaimer: The Content does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Nothing in this newsletter should be construed as a personal recommendation or advice to buy, sell, or hold any investment or security. All Content is provided for general informational purposes only and should not be relied upon for making investment decisions. You should not make any investment decision based solely on the Content without first consulting with qualified financial advisors, conducting your own research, and considering your individual financial circumstances, investment objectives, and risk tolerance. To read our full disclaimer, click here.
Well done!